TendoMend

Company Overview

Snapshot

Founded in February 2019 by Ehud (Udi) Almon and Ioannis Valavanis, TendoMend operates with 1–10 employees. The company has raised $3M across one funding round from one investor. In March 2019, TendoMend secured seed funding from NGT3.

Business overview

TendoMend is a Health Tech & Life Sciences company focused on developing a minimally invasive implant and deployment system for tendon repair. Its core product, the Dynamic Tendon Grip (DTG) device, aims to replace traditional suturing by providing an external embrace of the tendon, preventing damage and maintaining the original profile. This technology is designed to shorten and simplify surgical procedures, ensure repeatable outcomes, and facilitate early-active rehabilitation, serving the medical devices, surgery, rehabilitation, and orthopedics sectors globally.

Company Intelligence Q&A

What is TendoMend's primary product?

TendoMend's primary product is the Dynamic Tendon Grip (DTG) device, a miniaturized implant and dedicated applicator designed for minimally invasive tendon repair.

When was TendoMend founded and by whom?

TendoMend was founded in February 2019 by Ehud (Udi) Almon and Ioannis Valavanis.

What is the total capital raised by TendoMend?

TendoMend has raised a total of $3M across one funding round.

What is the core technology behind TendoMend's solution?

The core technology involves a minimally invasive implant that uses an external embrace to grip the tendon, aiming to provide a stronger, less traumatic connection while maintaining the tendon's original profile for smooth gliding and reduced post-surgery complications.

What is the current status of TendoMend?

TendoMend is currently Non-Active and ceased to operate in July 2025.